HDL-C

What HDL-C Measures

HDL (high-density lipoprotein) carries cholesterol from peripheral tissues back to the liver for excretion or reuse - a process called reverse cholesterol transport. HDL has historically been called "good cholesterol" because higher levels associate with lower cardiovascular risk.

The relationship is more nuanced than originally thought. Pharmacologically RAISING HDL hasn't reliably reduced CV events in trials (CETP inhibitor trials famously failed). The protective effect appears to require functional HDL - not just elevated levels.

What Affects This Biomarker

HDL is influenced by: aerobic exercise (one of the strongest non-pharma raisers), alcohol intake (modestly raises), genetics (large individual variance), body fat (visceral fat lowers), insulin resistance (lowers), smoking (lowers), saturated fat (modestly raises), low-carb diets (modestly raise), and pharmacologic agents - niacin raises modestly; statins modestly raise; GLP-1 agonists modestly raise.

In the Context of Peptide Protocols

Don't chase HDL aggressively in isolation. Focus on ApoB and the Triglycerides/HDL ratio (>3 = atherogenic dyslipidemia signal). On GLP-1s, expect modest HDL improvements alongside primary triglyceride and ApoB shifts. Very low HDL (<35) warrants attention - usually correctable with exercise + body composition work.

Deep Dive

HDL-C is a cargo count, not a function test

The number on your lipid panel labeled HDL-C measures one thing only: the total mass of cholesterol being carried inside your high-density lipoprotein particles at the moment of the draw. It does not count how many HDL particles you have, how large they are, or, most importantly, how well they actually do their job. This distinction is the single most useful thing to understand about the marker.

Two people can share an identical HDL-C of 55 mg/dL while having very different numbers of particles and very different particle function. The job that matters is cholesterol efflux capacity: the ability of HDL to pull cholesterol out of the foam cells buried in an artery wall and shuttle it back toward the liver. Khera et al. (New England Journal of Medicine, 2011) measured this directly and found that efflux capacity tracked with lower coronary disease independent of the HDL-C number itself. Rohatgi et al. (NEJM, 2014, Dallas Heart Study) confirmed that better efflux capacity predicted fewer future cardiovascular events even after adjusting for HDL-C. In other words, the standard lab value is a crude stand-in for the function that actually matters for arterial risk.

Why raising HDL with drugs never worked

The idea that a higher HDL-C number is inherently protective has been tested harder than almost any hypothesis in cardiology, and it repeatedly failed. Two lines of evidence explain why.

- **Mendelian randomization.** Voight et al. (Lancet, 2012) studied people carrying genetic variants that raise HDL for life. If a high HDL number itself were protective, these people should have fewer heart attacks. They did not. Genetically higher HDL, decoupled from other lipid changes, showed no reduction in myocardial infarction risk. - **The CETP inhibitor graveyard.** Torcetrapib (ILLUMINATE, Barter et al., NEJM 2007) raised HDL-C by roughly 72 percent and increased deaths, partly through off-target effects on blood pressure and aldosterone. Anacetrapib (REVEAL, 2017) raised HDL-C by about 104 percent yet produced only a small benefit that was attributed to its non-HDL and LDL lowering, not to the large HDL rise.

The lesson is that HDL-C is a marker of a healthy metabolic state, not a lever you pull. What raises it matters more than the number. HDL that rises because you added aerobic exercise and lost visceral fat reflects genuinely more functional particles. HDL raised by a drug that forces cholesterol to accumulate in particles does not.

The U-shaped curve: higher is not always better

Clinicians once treated HDL as a marker where more is always better. Large population studies overturned that. Both the CANHEART cohort (Ko et al., Journal of the American College of Cardiology, 2016) and the Copenhagen studies (Madsen et al., European Heart Journal, 2017) found a U-shaped relationship between HDL-C and mortality. Risk was lowest in a broad middle band, roughly 50 to 80 mg/dL, and rose again at the extreme high end. In the Copenhagen analysis, all-cause mortality was lowest near 73 mg/dL in men and 93 mg/dL in women, then climbed again as HDL-C moved well into the 90s mg/dL and beyond, with the upturn sitting at a higher level in women than in men.

This is why an unusually high reading is a reason to look closer, not to celebrate. Extreme HDL elevations can reflect genetic variants that produce dysfunctional particles, heavy alcohol intake, or other issues. If your HDL-C is well above 90, the useful next step is to discuss the context with your clinician rather than assume you have won the lipid lottery.

Testing pitfalls specific to HDL

HDL-C is one of the more stable lipid measurements, which creates a false sense of security. A few things reliably distort it:

- **Acute inflammation and illness lower it.** HDL is a negative acute phase reactant. During an infection, injury, or flare of an inflammatory condition, HDL-C drops and the particles temporarily become dysfunctional. A reading taken while you are fighting a cold or recovering from hard illness will read artificially low. Retest when you are well. - **Fasting is not required, but timing still matters.** Unlike triglycerides, HDL-C does not swing much with a recent meal, so non-fasting draws are usually acceptable. Recent heavy alcohol, an intense endurance session in the prior day or two, or active rapid weight loss can each shift the value. - **Assay and unit confusion.** International labs report in mmol/L. Multiply mmol/L by roughly 38.7 to reach mg/dL. Track trends at the same lab to avoid mistaking assay drift for a real change.

Androgens, hormones, and the HDL crash

For the peptide and hormone-using audience this is the most important section. HDL-C is highly sensitive to sex hormones. Estrogen raises it, which is a large part of why premenopausal women typically run higher HDL than men. Androgens do the opposite.

Oral 17-alpha-alkylated anabolic steroids are notorious for driving HDL-C down sharply, sometimes into the teens or single digits, largely by upregulating hepatic lipase. Injectable testosterone and supraphysiologic anabolic use also lower HDL, though usually less dramatically than oral compounds. Anyone running testosterone or anabolic protocols who sees HDL collapse should treat that as an expected pharmacologic effect worth tracking over time and discussing with their clinician, not a lifestyle failure. This is a case where the number is genuinely telling you something about drug exposure.

Tracking HDL inside a protocol

The practical move is to stop watching HDL-C in isolation and watch it in context. The research consistently points to ratios and companions:

- **Triglyceride to HDL ratio** is a stronger metabolic signal than HDL alone and tracks insulin resistance and small dense LDL pattern. - **ApoB** is the better single measure of atherogenic particle burden. - **Trajectory over the same lab** beats any single reading.

On GLP-1 protocols such as semaglutide or tirzepatide, expect HDL-C to drift up modestly as visceral fat falls, while triglycerides and ApoB do the heavier lifting. Monitor HDL as one panel line among several, log it alongside body composition and training changes, and bring unexpected extremes, whether very low from anabolic use or very high from unknown cause, to your clinician rather than reacting to the isolated number.

Peptides That Commonly Move HDL-C

Conditions That Track HDL-C

Frequently Asked Questions

Where This Fits in Your Panel

HDL-C is one marker on a fuller panel. The Peptide Blood Work Checklist lays out the complete baseline panel, what to add by protocol type, and when to retest.

Upload any lab PDF and MyProtocolStack maps your values to HDL-C and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.